Mantle Cell Lymphoma Epidemiology Forecast to 2030

Mantle Cell Lymphoma Epidemiology Forecast to 2030

“Delveinsight Business Research”
DelveInsight’s ‘Mantle Cell Lymphoma Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Mantle Cell Lymphoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Mantle Cell Lymphoma (MCL) is typically an aggressive, rare, form of non-Hodgkin lymphoma (NHL) that arises from cells originating in the “mantle zone”. The abnormal B Lymphocytes start to collect in the lymph nodes or body organs. They can then form tumors and begin to cause problems within the lymphatic system or the organ where they are growing.

About 85% of patients with Mantle Cell Lymphoma have a characteristic genetic lesion known as reciprocal translocation which is a major cause of MCL. In this genetic change, the short segment of one chromosome is moved to another chromosome. This change is considered a driver in the behaviour of MCL, which likely works together with other genetic defects to cause MCL.

MCL is characterized by specific subsets of symptoms such as fever, night sweats, generalized enlargement of lymph nodes (lymphadenopathy), fatigue, abdominal distention from an enlarged spleen, abdominal decision from an enlarged liver and weight loss. Spread of cancer into other organs (extranodal spread) may produce organ-specific symptoms. 

The DelveInsight Mantle Cell Lymphoma epidemiology report gives a thorough understanding of the Mantle Cell Lymphoma by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

It also provides treatment algorithms and treatment guidelines for Mantle Cell Lymphoma in the US, Europe, and Japan. The report covers the detailed information of the Mantle Cell Lymphoma epidemiology scenario in seven major countries (US, EU5, and Japan).

 

Key Highlights Of The Report

Age is a typical risk factor for MCL, the median age of MCL onset is 60 years of age with an age range of 35-85 years.

According to the Leukemia and Lymphoma Society, Mantle cell Lymphoma patients represent only about six per cent (6%) of all new cases of NHL in the United States.

As per American Cancer Society, B-cell NHL accounts for about 85% of the total cases of NHL.

According to a study titled “Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France” conducted by Christophe Leux et.al., over the period of 2002-2006, the age-standardised incidence rate of MCL (per 100,000) was 0.72 in men and 0.17 in women.

 Mantle Cell Lymphoma Epidemiology Forecast

Request for Sample Pages: 

https://www.delveinsight.com/sample-request/mantle-cell-lymphoma-epidemiology-forecast

Mantle Cell Lymphoma Epidemiology

Delveinsight’s Mantle Cell Lymphoma epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. 

The Mantle Cell Lymphoma epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. 

The Mantle Cell Lymphoma epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. 

It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 

Scope of the Report

  • The report provides insight into the historical and forecasted patient pool of Mantle Cell Lymphoma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.

  • The report assesses the disease risk and burden and highlights the unmet needs of Mantle Cell Lymphoma.

  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

  • The Mantle Cell Lymphoma report provides a detailed overview explaining Mantle Cell Lymphoma causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.

  • The Mantle Cell Lymphoma Epidemiology Report and Model provide an overview of the risk factors and global trends of Mantle Cell Lymphoma in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan).

  • The report provides the segmentation of the Mantle Cell Lymphoma epidemiology. 

 

Key Questions Covered In The Mantle Cell Lymphoma Report Include:

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Mantle Cell Lymphoma?

  • What are the key findings pertaining to the Mantle Cell Lymphoma epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Mantle Cell Lymphoma across the 7MM during the forecast period (2017-2030)?

  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What is the disease risk, burden and unmet needs of the Mantle Cell Lymphoma?

  • What are the currently available treatments of Mantle Cell Lymphoma?

 

Key Benefit of Mantle Cell Lymphoma Epidemiology Report 

  • The Mantle Cell Lymphoma Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Mantle Cell Lymphoma market

  • Quantify patient populations in the global Mantle Cell Lymphoma market to improve product design, pricing, and launch plans

  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Mantle Cell Lymphoma therapeutics in each of the markets covered

  • Understand the magnitude of Mantle Cell Lymphoma population by its epidemiology

  • The Mantle Cell Lymphoma Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Table of Contents

  1. Key Insights 

  2. Executive Summary of Mantle Cell Lymphoma

  3. Mantle Cell Lymphoma Disease Background and Overview

  • Mantle Cell Lymphoma Sign and Symptoms

  • Mantle Cell Lymphoma Pathophysiology

  • Mantle Cell Lymphoma Risk Factors

  • Mantle Cell Lymphoma Diagnosis

  1. Mantle Cell Lymphoma Patient Journey

  2. Mantle Cell Lymphoma Epidemiology and Patient Population

  3. Mantle Cell Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

  4. KOL Views on Mantle Cell Lymphoma 

  5. Mantle Cell Lymphoma Unmet Needs

  6. Appendix

  7. DelveInsight Capabilities

  8. Disclaimer

*The table of contents is not exhaustive; will be provided in the final report

 

About  DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

 

Related Reports-

Mantle Cell Lymphoma Market Insight, Epidemiology and Market Forecast 2030
DelveInsight’ s Mantle Cell Lymphoma Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in-depth understanding of historical and forecasted epidemiology.

 

Mantle Cell Lymphoma Pipeline Insights, 2020
Mantle Cell Lymphoma Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Mantle Cell Lymphoma market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/